Ni Luohang, Xu Jianing, Li Quanpeng, Ge Xianxiu, Wang Fei, Deng Xueting, Miao Lin
Medical Center for Digestive Diseases, Second Affiliated Hospital, Nanjing Medical University, Nanjing, Jiangsu, People's Republic of China.
Cancer Manag Res. 2024 Jul 29;16:941-963. doi: 10.2147/CMAR.S474348. eCollection 2024.
Biliary tract cancer (BTC) represents a challenging malignancy characterized by aggressive behavior, high relapse rates, and poor prognosis. In recent years, immunotherapy has revolutionized the treatment landscape for various cancers, but its efficacy in BTC remains limited. This article provides a comprehensive overview of the advances in preclinical and clinical studies of immunotherapy for BTC. We explore the potential of immune checkpoint inhibitors in reshaping the management of BTC. Despite disappointing results thus far, ongoing clinical trials are investigating the combination of immunotherapy with other treatment modalities. Furthermore, research on the tumor microenvironment has unveiled novel targets for immunotherapeutic interventions. By understanding the current state of immunotherapy in BTC and highlighting future directions, this article aims to fuel further exploration and ultimately improve patient outcomes in this challenging disease.
胆管癌（BTC）是一种具有挑战性的恶性肿瘤，其特点是侵袭性强、复发率高且预后不良。近年来，免疫疗法彻底改变了各种癌症的治疗格局，但其在BTC中的疗效仍然有限。本文全面概述了BTC免疫疗法在临床前和临床研究方面的进展。我们探讨了免疫检查点抑制剂在重塑BTC治疗中的潜力。尽管目前结果令人失望，但正在进行的临床试验正在研究免疫疗法与其他治疗方式的联合应用。此外，对肿瘤微环境的研究揭示了免疫治疗干预的新靶点。通过了解BTC免疫疗法的现状并突出未来方向，本文旨在推动进一步探索，并最终改善这种具有挑战性疾病的患者预后。
